Hold Rating on Rocket Pharmaceuticals Amid Strategic Shifts and Regulatory Challenges

In a report released today, Mani Foroohar from Leerink Partners reiterated a Hold rating on Rocket Pharmaceuticals, with a price target of $7.00.

Mani Foroohar has given his Hold rating due to a combination of factors surrounding Rocket Pharmaceuticals’ recent strategic decisions. The company has voluntarily withdrawn its BLA for RP-L102 in Fanconi Anemia, following a similar withdrawal for European approval earlier. This move aligns with Rocket’s recent strategic shift, where they paused development on certain projects and are seeking partnerships.
While there was some hope that RP-L102 could attract a partner during the approval process, the withdrawal indicates limited interest in their lentiviral assets. Despite this, ongoing partnership discussions and future trials, such as the pivotal Danon trial, are expected to maintain investor interest. The company’s focus on resolving regulatory issues and potential financial stabilization through a priority review voucher also contribute to the Hold rating.

Foroohar covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, and RegenXBio. According to TipRanks, Foroohar has an average return of -2.3% and a 45.79% success rate on recommended stocks.